Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenus
5
5
5
5
7
9
Croissance des revenus (H/H)
-57.99%
0%
0%
-28.99%
-22%
-40%
Coût des ventes
1
1
1
2
1
4
Bénéfice brut
3
3
4
3
6
5
Vente, Général et Administration
8
8
9
12
15
15
Recherche et développement
2
2
2
1
1
0
Frais d'exploitation
14
14
17
19
24
22
Autres revenus (charges) non opérationnels
0
0
2
--
--
--
Bénéfice avant impôts
-14
-14
-8
-20
-8
-22
Charge d'impôt sur le revenu
0
0
0
0
0
-1
Bénéfice net
-26
-26
-13
-20
-8
-20
Croissance du bénéfice net
18%
100%
-35%
150%
-60%
-38%
Actions en circulation (diluées)
0.4
0.32
0.08
0.08
0.04
0.03
Variation des actions (H-H)
-81%
269%
5%
90%
12%
0%
EPS (dilué)
-66.27
-83.46
-158.71
-241.99
-206.38
-530.26
Croissance du EPS
547%
-47%
-34%
17%
-61%
-37%
Flux de trésorerie libre
-2
-2
-7
-12
-11
-15
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
60%
60%
80%
60%
85.71%
55.55%
Marge opérationnelle
-200%
-200%
-260%
-300%
-257.14%
-188.88%
Marge bénéficiaire
-520%
-520%
-260%
-400%
-114.28%
-222.22%
Marge du flux de trésorerie libre
-40%
-40%
-140%
-240%
-157.14%
-166.66%
EBITDA
-8
-8
-10
-10
-12
-11
Marge EBITDA
-160%
-160%
-200%
-200%
-171.42%
-122.22%
D&A pour le résultat opérationnel
2
2
3
5
6
6
EBIT
-10
-10
-13
-15
-18
-17
Marge EBIT
-200%
-200%
-260%
-300%
-257.14%
-188.88%
Taux d'imposition effectif
0%
0%
0%
0%
0%
4.54%
Statistiques clés
Clôture préc.
$0.007
Prix d'ouverture
$0.007
Plage de la journée
$0.007 - $0.007
Plage de 52 semaines
$0.002 - $16.25
Volume
17.0K
Volume moyen
198.7K
BPA (TTM)
-1.69
Rendement en dividend
--
Capitalisation boursière
$296.5K
Qu’est-ce que PTPI ?
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. The company is headquartered in New York City, New York and currently employs 18 full-time employees. The company went IPO on 2020-12-02. The firm is engaged in developing a software-as-a-service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch. In addition to the SaaS component, the platform is intended to incorporate software as a medical device (SaMD) capabilities, transforming traditional OTC medications into digitally enabled solutions. The SaMD interface seeks to be designed as customized and branded to pharmaceutical therapy and established as a specific application pathway to that therapy. Together, it aims to develop the SaaS and SaMD components to create a scalable, licensable platform that supports various classes of medications across the pharmaceutical industry, assisting pharmaceutical companies achieve regulatory approval, while delivering consumer-focused healthcare solutions.